Literature DB >> 26778441

Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled Trials.

Jacopo Giuliani1, Andrea Bonetti2.   

Abstract

Entities:  

Keywords:  Advanced NSCLC; Costs of drugs; First-line chemotherapy; Randomized phase III trials; Targeted therapies

Mesh：

Substances：

Year:  2015        PMID： 26778441     DOI： 10.1016/j.cllc.2015.12.005

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  2 in total

1.  Cost-effectiveness analysis of different sequences of osimertinib administration for epidermal growth factor receptor-mutated non-small-cell lung cancer.

Authors:  Wenqian Li; Lei Qian; Wei Li; Xiao Chen; Hua He; Huimin Tian; Yuguang Zhao; Xu Wang; Jiuwei Cui
Journal:  Exp Ther Med       Date:  2021-02-10       Impact factor: 2.447

2.  LncRNA SNHG15 regulates EGFR-TKI acquired resistance in lung adenocarcinoma through sponging miR-451 to upregulate MDR-1.

Authors:  Jiayuan Huang; Banzhou Pan; Guohao Xia; Jingni Zhu; Chenchen Li; Jifeng Feng
Journal:  Cell Death Dis       Date:  2020-07-13       Impact factor: 8.469
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.